Alcohol Addiction (AA) – Pipeline Insights – 2018

SKU: DPI45 | Last Updated On: 2019-04-09 | No. of Pages: 196 | Available Formats

Alcohol Addiction

  • The “Alcohol Addiction (AA) – Pipeline Insights, 2018″ report covers an in-depth analysis of Alcohol Addiction drug molecules currently undergoing clinical studies.
  • It provides a deep understanding of potential Alcohol Addiction drug molecules across all drug development phases. The report assesses the pipeline Alcohol Addiction molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products), molecule type (small molecules, biologics and others), drug target, mechanism of action (MoA), and route of administration (oral, IV, and others). The report provides a snapshot of discontinued and dormant drugs too.
  • In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
  • The report covers company profiles key players in developing Alcohol Addiction drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.


The scope of the report

• Provides comprehensive understanding of active Alcohol Addiction pipeline drug candidates

• Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.

• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration

• Provides a comparative analysis of key marketed products and pipeline drug candidates

• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators

• Provides key info on players involved in clinical R&D of Alcohol Addiction drug candidates.

• Provides in-depth coverage of key news related to Alcohol Addiction drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.


Reasons To Buy

• To obtain an understanding of the current Alcohol Addiction pipeline landscape.

• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.

• To valuably optimize R&D activities in-line with robust therapeutic drug markets.

• To devise strategic initiatives by identifying prospective partners with progressing projects.

Alcohol Addiction

  • Alcohol addiction (AA) refers to psychological and physical dependency on alcohol. Alcohol dependence is considered a brain disease that shows alcohol-induced disturbances in brain structure, neurochemistry, and behavior. Symptoms are less involved in extracurricular activities, restlessness, depression, and inability to control drinking and violent behavior.
  • Risk factors include age, family history, depression, and other mental health problems. Alcohol consumption will likely lead to other chronic diseases such as liver cirrhosis, epilepsy, poisoning, and several types of cancer.
  • Treatment for alcohol dependence consists of behavioral therapy, which is generally provided alongside medicines. Abstinence and reduction goals are considered as part of a comprehensive treatment approach for alcohol dependence. 
  • Also, support from those close to the patient is very important. To overcome this issue, there are several customized addiction treatment centers that offer detoxification and rehabilitation programs. New drugs will also challenge the conventional wisdom around Alcohol addiction being the primary ‒ the often only solution to substance abuse.
  • The U.S. Food and Drug Administration currently approved only three medications for the treatment of alcohol addiction.
  • These medications are not prescribed to people who are still drinking alcohol. They are only given for those who already stopped drinking and are trying to maintain abstinence. Some of the current FDA approved drugs used in the treatment of alcoholism are Naltrexone (Vivitrol)– restricts the amount of the dopamine that creates in response to alcohol and helps to limit alcohol cravings, Acamprosate (Campral) – stabilizes chemical imbalances in the brains of patients and also helps in preventing relapse.
  • It also reduces anxiety and mood swings and improves sleep, Antabuse (Disulfiram) – used as a deterrent to drinking because of the negative physical side effects when mixed with alcohol. Both Naltrexone and Acamprosate are antagonist therapies that work in the brain by binding to opiate receptors and work against the euphoric effects of addictive substances such as alcohol and heroin. Antabuse is considered as more aversion therapy.
  • The alcohol addiction clinical pipeline consists of various drug molecules under different phases of drug development and shows that a higher number of studies is found to be in early phase, Phase I and Phase II trials compared to phase III trials.
  • The drugs in the early phase, Phase I of drug development include PT150 by POPTest Oncology, Biological Fecal Microbial Transplant by OpenBiome and the drugs in Phase II trials include XR-NTX+HRC by Alkermes Inc, Behavioral RBIRT by Polaris Health Directions, PF-05190457, Doxazosin, Psilocybin, and Pioglitazone. Some of the drugs in Phase III trials of drug development include Acamprostate calcium, Topiramate, Naltrexone, Zonisamide, Nalmefene (Selincro), BACLOFEN, Memantine, Aripiprazole, and Intranasal Ketamine.
  • The market is likely to be driven by the increasing government initiatives to augment the awareness level of consumers regarding alcohol addiction and deploying favorable reimbursement policies for AA therapy.
  • The continual introduction of innovative therapies and drugs for addiction treatment is also expected to propel the market growth over the next few years.
  • As the worldwide addiction treatment market future looks thriving, it may face several challenges in the years to come. The length of treatment procedures, which need time-to-time monitoring and multiple interventions, is projected to hamper the growth trajectory of this market over the forthcoming years
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Get your FREE SAMPLE PROPOSAL with a single click!